Roche kidney drug's Phase 3 win sets up path to accelerated approval

Roche moves closer to entering an increasingly crowded kidney disease market where Novartis, Calliditas, Travere, Otsuka and Vera already have approved drugs. The Swiss pharma reported interim Phase 3 results Wednesday ...